person · Reporting owner

Mansukani Sharad

Disclosed activity across 6 companies

Tapewire entity: 41315
SEC CIK: 0001402190

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Endo International plcENDP · Entity 124463	Director	June 12, 2019	June 14, 2019
Surgical Care Affiliates, Inc.SCAI · Entity 177510	Director	March 24, 2017	March 24, 2017
agilon health, inc.AGL · Entity 4698	Director	June 02, 2026	June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Endo International plc

Report date June 12, 2019 · Filed June 14, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	71,523	Ending reported balance After 2019-06-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-06-12 · Grant · Acquired 53,812 · Balance 97,352 F1: These ordinary shares were granted to Dr. Mansukani on June 12, 2019 in consideration of his services on Endo International plc's Board of Directors. Row 2 · 2019-06-12 · Tax withholding · Disposed 25,829 · Balance 71,523 F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Mansukani's tax withholding obligations on shares acquired on June 12, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: These ordinary shares were granted to Dr. Mansukani on June 12, 2019 in consideration of his services on Endo International plc's Board of Directors.

F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Mansukani's tax withholding obligations on shares acquired on June 12, 2019.

Surgical Care Affiliates, Inc.

Report date March 24, 2017 · Filed March 24, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-03-24 transaction · row 1 1 source row Row 1 · 2017-03-24 · Disposition to issuer · Disposed 11,569 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Reorganization, dated January 7, 2017, (the "Merger Agreement," and the merger contemplated thereby, the "Merger") by and among Surgical Care Affiliates, Inc. ("SCA"), UnitedHealth Group Incorporated ("UHG"), Spartan Merger Sub 1, Inc., and Spartan Merger Sub 2, LLC. F2: Reflects 11,569 shares of Common Stock underlying restricted stock units ("RSUs") of the issuer, all of which were subject to time-based vesting. Each RSU represents a contingent right to acquire one share of Common Stock. Immediately prior to the effective time of the Merger (the "Effective Time"), all of these RSUs were vested (8,441 of which had previously vested and 3,128 of which vested in connection with the Merger) and settled in shares of Common Stock. F3: Pursuant to the Merger Agreement, at the Effective Time each share of Common Stock was cancelled and converted into the right to receive $11.40 in cash and a number of shares of UHG common stock equal to $45.60 divided by $169.42 (which represents the volume weighted average of the closing sale prices per share of UHG common stock on the New York Stock Exchange on each of the five full consecutive trading days ending on and including March 21, 2017, the third business day prior to the final expiration date of the exchange offer by Spartan Merger Sub 1, Inc. to acquire all of the outstanding shares of Common Stock (the "Exchange Offer")), with the fractional shares being paid in cash, as provided in the Merger Agreement.
Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.10 · Expires 2021-08-01	Direct	0	Reported balance After 2017-03-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-03-24 · Disposition to issuer · Disposed 9,921 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Reorganization, dated January 7, 2017, (the "Merger Agreement," and the merger contemplated thereby, the "Merger") by and among Surgical Care Affiliates, Inc. ("SCA"), UnitedHealth Group Incorporated ("UHG"), Spartan Merger Sub 1, Inc., and Spartan Merger Sub 2, LLC. F5: Pursuant to the Merger Agreement, at the Effective Time each outstanding SCA stock option was cancelled and converted into an option to purchase UHG common stock (rounded down to the nearest whole number) equal to the product of (x) the number of shares subject to such SCA stock option immediately prior to the Effective Time and (y) $57 divided by $169.42 (which represents the volume weighted average of the closing sale prices per share of UHG common stock on the New York Stock Exchange on each of the five full consecutive trading days ending on and including March 21, 2017, the third business day prior to the final expiration date of the Exchange Offer), rounded down to the nearest whole share (such quotient, the "Equity Award Conversion Ratio"), at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such SCA stock option immediately prior to the Effective Time divided by (B) the Equity Award Conversion Ratio. F4: The options became vested as to all of the shares of Common Stock underlying such options on June 29, 2012 and became exercisable on September 16, 2013.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Reorganization, dated January 7, 2017, (the "Merger Agreement," and the merger contemplated thereby, the "Merger") by and among Surgical Care Affiliates, Inc. ("SCA"), UnitedHealth Group Incorporated ("UHG"), Spartan Merger Sub 1, Inc., and Spartan Merger Sub 2, LLC.

F2: Reflects 11,569 shares of Common Stock underlying restricted stock units ("RSUs") of the issuer, all of which were subject to time-based vesting. Each RSU represents a contingent right to acquire one share of Common Stock. Immediately prior to the effective time of the Merger (the "Effective Time"), all of these RSUs were vested (8,441 of which had previously vested and 3,128 of which vested in connection with the Merger) and settled in shares of Common Stock.

F3: Pursuant to the Merger Agreement, at the Effective Time each share of Common Stock was cancelled and converted into the right to receive $11.40 in cash and a number of shares of UHG common stock equal to $45.60 divided by $169.42 (which represents the volume weighted average of the closing sale prices per share of UHG common stock on the New York Stock Exchange on each of the five full consecutive trading days ending on and including March 21, 2017, the third business day prior to the final expiration date of the exchange offer by Spartan Merger Sub 1, Inc. to acquire all of the outstanding shares of Common Stock (the "Exchange Offer")), with the fractional shares being paid in cash, as provided in the Merger Agreement.

F4: The options became vested as to all of the shares of Common Stock underlying such options on June 29, 2012 and became exercisable on September 16, 2013.

F5: Pursuant to the Merger Agreement, at the Effective Time each outstanding SCA stock option was cancelled and converted into an option to purchase UHG common stock (rounded down to the nearest whole number) equal to the product of (x) the number of shares subject to such SCA stock option immediately prior to the Effective Time and (y) $57 divided by $169.42 (which represents the volume weighted average of the closing sale prices per share of UHG common stock on the New York Stock Exchange on each of the five full consecutive trading days ending on and including March 21, 2017, the third business day prior to the final expiration date of the Exchange Offer), rounded down to the nearest whole share (such quotient, the "Equity Award Conversion Ratio"), at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such SCA stock option immediately prior to the Effective Time divided by (B) the Equity Award Conversion Ratio.

agilon health, inc.

Report date June 02, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	56,242	Reported balance After 2026-06-02 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-02 · Grant · Acquired 2,133 · Balance 56,242 F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director. F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026. F3: Includes restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director.

F2: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.

F3: Includes restricted stock units.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Convey Health Solutions Holdings, Inc.

Report date October 07, 2022 · Filed October 12, 2022

Section 16 reporting ended · disclosed 2022-10-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.94 · Expires 2030-03-02	Direct	Reported balance After 2022-10-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-10-07 · Disposition to issuer · Disposed 235,935 · Balance 0 F1: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F4: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2030-03-02	Direct	Reported balance After 2022-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-07 · Disposition to issuer · Disposed 438,165 · Balance 0 F1: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F4: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. F5: Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-07 · Disposition to issuer · Disposed 54,250 · Balance 0 F6: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01. F7: Represents 54,250 RSUs. RSUs are scheduled to vest on March 28, 2023, subject to Mr. Mansukani's continued service through the vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. F1: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share.

Filing footnotes · ownership attribution and instrument terms

F1: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares.

F2: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share.

F3: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01.

F4: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics.

F5: Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders.

F6: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01.

F7: Represents 54,250 RSUs. RSUs are scheduled to vest on March 28, 2023, subject to Mr. Mansukani's continued service through the vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock.

IMS Health Holdings, Inc.

Report date October 03, 2016 · Filed October 03, 2016

Section 16 reporting ended · disclosed 2016-10-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-10-03 transaction · row 1 1 source row Row 1 · 2016-10-03 · Disposition to issuer · Disposed 42,840 · Balance 0 F1: On May 3, 2016, the issuer and Quintiles Transnational Holdings, Inc. ("Quintiles") entered into an Agreement and Plan of Merger pursuant to which on October 3, 2016 the issuer merged with and into Quintiles (the "merger"), the separate existence of the issuer ceased and Quintiles will continue as the surviving corporation, operating under the name Quintiles IMS Holdings, Inc. F2: Disposed of pursuant to merger agreement in exchange for 16,450 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger.
Employee Stock Optoin (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2020-07-20	Direct	Reported balance After 2016-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: This option was assumed by Quintiles in the merger and replaced with an option to purchase 7,680 shares of Quintiles IMS Holdings, Inc. common stock at a price of $26.05 per share.
Employee Stock Optoin (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.80 · Expires 2020-07-20	Direct	Reported balance After 2016-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: This option was assumed by Quintiles in the merger and replaced with an option to purchase 3,840 shares of Quintiles IMS Holdings, Inc. common stock at a price of $15.11 per share.
Employee Stock Optoin (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2020-07-20	Direct	Reported balance After 2016-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: This option was assumed by Quintiles in the merger and replaced with an option to purchase 7,680 shares of Quintiles IMS Holdings, Inc. common stock at a price of $8.34 per share.

Filing footnotes · ownership attribution and instrument terms

F1: On May 3, 2016, the issuer and Quintiles Transnational Holdings, Inc. ("Quintiles") entered into an Agreement and Plan of Merger pursuant to which on October 3, 2016 the issuer merged with and into Quintiles (the "merger"), the separate existence of the issuer ceased and Quintiles will continue as the surviving corporation, operating under the name Quintiles IMS Holdings, Inc.

F2: Disposed of pursuant to merger agreement in exchange for 16,450 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger.

F3: This option was assumed by Quintiles in the merger and replaced with an option to purchase 7,680 shares of Quintiles IMS Holdings, Inc. common stock at a price of $26.05 per share.

F4: This option was assumed by Quintiles in the merger and replaced with an option to purchase 3,840 shares of Quintiles IMS Holdings, Inc. common stock at a price of $15.11 per share.

F5: This option was assumed by Quintiles in the merger and replaced with an option to purchase 7,680 shares of Quintiles IMS Holdings, Inc. common stock at a price of $8.34 per share.

KINDRED HEALTHCARE, INC

Report date July 02, 2018 · Filed July 02, 2018

Section 16 reporting ended · disclosed 2018-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-07-02 transaction · row 1 1 source row Row 1 · 2018-07-02 · Disposition to issuer · Disposed 38,512 · Balance 0

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 02, 2026 Filed Jun 5, 2026 01:55 UTC	agilon health, inc. AGL · Entity 4698	GrantCommon Stock	2,133	$0.00	$0.00	Disclosure SEC source: 0001628280-26-041021 · wk-form4_1780624549.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,242 F1 · shares: Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director. F2 · balance_after: The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026. F3 · balance_after: Includes restricted stock units. Read SEC document
May 28, 2025 Filed May 30, 2025 22:24 UTC	agilon health, inc. AGL · Entity 4698	GrantCommon Stock	78,724	$0.00	$0.00	Disclosure SEC source: 0001628280-25-028714 · wk-form4_1748643848.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,352,757 F1 · shares: Restricted stock units that vest in full on May 28, 2026, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document
May 29, 2024 Filed Jun 1, 2024 00:55 UTC	agilon health, inc. AGL · Entity 4698	GrantCommon Stock	32,119	$0.00	$0.00	Disclosure SEC source: 0001628280-24-026124 · wk-form4_1717203301.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,274,033 F1 · shares: Restricted stock units that vest in full on May 29, 2025, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document
April 14, 2023 Filed Apr 18, 2023 20:47 UTC	agilon health, inc. AGL · Entity 4698	GrantCommon Stock	5,622	$0.00	$0.00	Disclosure SEC source: 0001209191-23-024670 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,241,914 F1 · shares: Restricted stock units that vest in full on April 14, 2024, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document
October 07, 2022 Filed Oct 12, 2022 23:33 UTC	Convey Health Solutions Holdings, Inc. CNVY · Entity 123140	Disposition to issuerRestricted Stock Units · Derivative	54,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-22-017706 · dp182278_4-mansukani.xml · derivative · entry 3 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 54,250 shares Expires not disclosed F6 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01. F7 · derivative.exercise_price: Represents 54,250 RSUs. RSUs are scheduled to vest on March 28, 2023, subject to Mr. Mansukani's continued service through the vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. F1 · date: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2 · date: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F6 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01. F7 · derivative.exercise_date: Represents 54,250 RSUs. RSUs are scheduled to vest on March 28, 2023, subject to Mr. Mansukani's continued service through the vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. F7 · derivative.expiration_date: Represents 54,250 RSUs. RSUs are scheduled to vest on March 28, 2023, subject to Mr. Mansukani's continued service through the vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. Read SEC document
October 07, 2022 Filed Oct 12, 2022 23:33 UTC	Convey Health Solutions Holdings, Inc. CNVY · Entity 123140	Disposition to issuerStock Option (right to buy) · Derivative	438,165	Not disclosed Strike: $6.76	Not disclosed	Disclosure SEC source: 0000950103-22-017706 · dp182278_4-mansukani.xml · derivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 438,165 shares Expires 2030-03-02 F1 · security: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2 · security: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F4 · security: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. F5 · derivative.exercise_price: Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders. F1 · date: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2 · date: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F4 · derivative.exercise_date: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. Read SEC document
October 07, 2022 Filed Oct 12, 2022 23:33 UTC	Convey Health Solutions Holdings, Inc. CNVY · Entity 123140	Disposition to issuerStock Option (right to buy) · Derivative	235,935	Not disclosed Strike: $7.94	Not disclosed	Disclosure SEC source: 0000950103-22-017706 · dp182278_4-mansukani.xml · derivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 235,935 shares Expires 2030-03-02 F1 · security: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2 · security: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F4 · security: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. F1 · date: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"), resulting in the reporting person beneficially owning 2,066 Surviving Corporation Shares. F2 · date: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F4 · derivative.exercise_date: The options, together representing a right to purchase 674,100 shares, consist of (i) 337,050 time-vesting options and (ii) 337,050 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. Read SEC document
April 14, 2022 Filed Apr 20, 2022 20:56 UTC	agilon health, inc. AGL · Entity 4698	GrantCommon Stock	6,936	$0.00	$0.00	Disclosure SEC source: 0001209191-22-025015 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,292 F1 · shares: Restricted stock units that vest in full on April 14, 2023, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document
March 28, 2022 Filed Mar 30, 2022 20:42 UTC	Convey Health Solutions Holdings, Inc. CNVY · Entity 123140	GrantRestricted Stock Units · Derivative	54,250	$0.00	$0.00	Disclosure SEC source: 0001104659-22-040171 · tm2210674-6_4seq1.xml · derivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,250 Underlying: Common Stock, par value $0.01 per share · 54,250 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest on the earlier of March 28, 2023 and the day immediately prior to the date of the next annual meeting of the shareholders of Convey Health Solutions Holdings, Inc. (the "Issuer") following March 28, 2022, subject to Mr. Mansukani's continued service with the Issuer through the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will be settled in common stock. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest on the earlier of March 28, 2023 and the day immediately prior to the date of the next annual meeting of the shareholders of Convey Health Solutions Holdings, Inc. (the "Issuer") following March 28, 2022, subject to Mr. Mansukani's continued service with the Issuer through the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will be settled in common stock. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest on the earlier of March 28, 2023 and the day immediately prior to the date of the next annual meeting of the shareholders of Convey Health Solutions Holdings, Inc. (the "Issuer") following March 28, 2022, subject to Mr. Mansukani's continued service with the Issuer through the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will be settled in common stock. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:20 UTC	agilon health, inc. AGL · Entity 4698	Exercise / conversionOptions (Rights to Buy) · Derivative	156,250	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001209191-21-056204 · doc4.xml · derivative · entry 3 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,750 Underlying: Common Stock · 156,250 shares Expires 2027-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on April 27, 2017, and fully vested on July 1, 2020. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:20 UTC	agilon health, inc. AGL · Entity 4698	SaleCommon Stock	156,250	$28.98	$4,528,125.00	Disclosure SEC source: 0001209191-21-056204 · doc4.xml · nonDerivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,356 F1 · balance_after: Includes restricted stock units. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:20 UTC	agilon health, inc. AGL · Entity 4698	Exercise / conversionCommon Stock	156,250	$1.00	$156,250.00	Disclosure SEC source: 0001209191-21-056204 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,385,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes restricted stock units. Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:28 UTC	agilon health, inc. AGL · Entity 4698	GrantCommon Stock	6,956	$0.00	$0.00	Disclosure SEC source: 0001209191-21-027019 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,356 F1 · shares: Restricted stock units that vests in full on April 14, 2022, subject to continued service as a director. Read SEC document
June 12, 2019 Filed Jun 14, 2019 23:32 UTC	Endo International plc ENDP · Entity 124463	Tax withholdingOrdinary Shares	25,829	$4.46	$115,197.34	Disclosure SEC source: 0001209191-19-037302 · doc4.xml · nonDerivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,523 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Mansukani's tax withholding obligations on shares acquired on June 12, 2019. Read SEC document
June 12, 2019 Filed Jun 14, 2019 23:32 UTC	Endo International plc ENDP · Entity 124463	GrantOrdinary Shares	53,812	$0.00	$0.00	Disclosure SEC source: 0001209191-19-037302 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,352 F1 · kind: These ordinary shares were granted to Dr. Mansukani on June 12, 2019 in consideration of his services on Endo International plc's Board of Directors. Read SEC document
July 02, 2018 Filed Jul 2, 2018 13:10 UTC	KINDRED HEALTHCARE, INC KND · Entity 165258	Disposition to issuerCommon Stock	38,512	$9.00	$346,608.00	Disclosure SEC source: 0001209191-18-040221 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
June 08, 2018 Filed Jun 12, 2018 20:16 UTC	Endo International plc ENDP · Entity 124463	Tax withholdingOrdinary Shares	15,019	$7.67	$115,195.73	Disclosure SEC source: 0001209191-18-037221 · doc4.xml · nonDerivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,540 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Mansukani's tax withholding obligations on shares acquired on June 8, 2018. Read SEC document
June 08, 2018 Filed Jun 12, 2018 20:16 UTC	Endo International plc ENDP · Entity 124463	GrantOrdinary Shares	31,291	$0.00	$0.00	Disclosure SEC source: 0001209191-18-037221 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,559 F1 · kind: These ordinary shares were granted to Dr. Mansukani on June 8, 2018 in consideration of his services on Endo International plc's Board of Directors. Read SEC document
November 08, 2017 Filed Nov 13, 2017 21:07 UTC	Endo International plc ENDP · Entity 124463	Tax withholdingOrdinary Shares	3,206	$6.09	$19,524.54	Disclosure SEC source: 0001209191-17-060276 · doc4.xml · nonDerivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,268 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Mansukani's tax withholding obligations on shares acquired. Read SEC document
November 08, 2017 Filed Nov 13, 2017 21:07 UTC	Endo International plc ENDP · Entity 124463	GrantOrdinary Shares	6,681	$0.00	$0.00	Disclosure SEC source: 0001209191-17-060276 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,474 F1 · kind: These ordinary shares were granted to Dr. Mansukani on November 8, 2017 in consideration of his anticipated services on Endo International plc's Board of Directors. Read SEC document
May 24, 2017 Filed May 25, 2017 12:12 UTC	KINDRED HEALTHCARE, INC KND · Entity 165258	GrantCommon Stock	14,852	$0.00	$0.00	Disclosure SEC source: 0001209191-17-035210 · doc4.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,512 F1 · shares: These shares represent restricted stock granted to the reporting person. These shares will fully vest on 5/24/2018. Read SEC document
March 24, 2017 Filed Mar 24, 2017 21:16 UTC	Surgical Care Affiliates, Inc. SCAI · Entity 177510	Disposition to issuerOptions to Purchase Common Stock · Derivative	9,921	Not disclosed Strike: $12.10	Not disclosed	Disclosure SEC source: 0000903423-17-000219 · mansukani.xml · derivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,921 shares Expires 2021-08-01 F1 · kind: Disposed of pursuant to the Agreement and Plan of Reorganization, dated January 7, 2017, (the "Merger Agreement," and the merger contemplated thereby, the "Merger") by and among Surgical Care Affiliates, Inc. ("SCA"), UnitedHealth Group Incorporated ("UHG"), Spartan Merger Sub 1, Inc., and Spartan Merger Sub 2, LLC. F5 · price: Pursuant to the Merger Agreement, at the Effective Time each outstanding SCA stock option was cancelled and converted into an option to purchase UHG common stock (rounded down to the nearest whole number) equal to the product of (x) the number of shares subject to such SCA stock option immediately prior to the Effective Time and (y) $57 divided by $169.42 (which represents the volume weighted average of the closing sale prices per share of UHG common stock on the New York Stock Exchange on each of the five full consecutive trading days ending on and including March 21, 2017, the third business day prior to the final expiration date of the Exchange Offer), rounded down to the nearest whole share (such quotient, the "Equity Award Conversion Ratio"), at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such SCA stock option immediately prior to the Effective Time divided by (B) the Equity Award Conversion Ratio. F4 · derivative.exercise_date: The options became vested as to all of the shares of Common Stock underlying such options on June 29, 2012 and became exercisable on September 16, 2013. Read SEC document
March 24, 2017 Filed Mar 24, 2017 21:16 UTC	Surgical Care Affiliates, Inc. SCAI · Entity 177510	Disposition to issuerCommon Stock	11,569	Not disclosed	Not disclosed	Disclosure SEC source: 0000903423-17-000219 · mansukani.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Reorganization, dated January 7, 2017, (the "Merger Agreement," and the merger contemplated thereby, the "Merger") by and among Surgical Care Affiliates, Inc. ("SCA"), UnitedHealth Group Incorporated ("UHG"), Spartan Merger Sub 1, Inc., and Spartan Merger Sub 2, LLC. F2 · shares: Reflects 11,569 shares of Common Stock underlying restricted stock units ("RSUs") of the issuer, all of which were subject to time-based vesting. Each RSU represents a contingent right to acquire one share of Common Stock. Immediately prior to the effective time of the Merger (the "Effective Time"), all of these RSUs were vested (8,441 of which had previously vested and 3,128 of which vested in connection with the Merger) and settled in shares of Common Stock. F3 · price: Pursuant to the Merger Agreement, at the Effective Time each share of Common Stock was cancelled and converted into the right to receive $11.40 in cash and a number of shares of UHG common stock equal to $45.60 divided by $169.42 (which represents the volume weighted average of the closing sale prices per share of UHG common stock on the New York Stock Exchange on each of the five full consecutive trading days ending on and including March 21, 2017, the third business day prior to the final expiration date of the exchange offer by Spartan Merger Sub 1, Inc. to acquire all of the outstanding shares of Common Stock (the "Exchange Offer")), with the fractional shares being paid in cash, as provided in the Merger Agreement. Read SEC document
March 02, 2017 Filed Mar 6, 2017 16:47 UTC	Surgical Care Affiliates, Inc. SCAI · Entity 177510	GrantCommon Stock	1,059	$0.00	$0.00	Disclosure SEC source: 0001590503-17-000046 · edgar.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,569 F1 · shares: Grant of restricted stock units of the issuer, vesting ratably in equal annual installments over a period of two years from March 2, 2017, pursuant to the Surgical Care Affiliates, Inc. 2016 Omnibus Long-Term Incentive Plan (the "Plan"), which is exempt under Rule 16b-3(d) of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 11,569 shares of Common Stock underlying restricted stock units ("RSUs") of the issuer, all of which are subject to time-based vesting. As of the date hereof, 8,441 of the RSUs were vested, with the remaining RSUs vesting on the following schedule: 978 RSUs vesting on June 4, 2017, 1,621 RSUs vesting on March 2, 2018 and 529 RSUs vesting on March 2, 2019. Each vested RSU is settled on the earlier of the individual's termination of employment (as defined in the Plan) or a change in control of the issuer. Read SEC document
October 03, 2016 Filed Oct 3, 2016 22:50 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerEmployee Stock Optoin (right to buy) · Derivative	20,000	Not disclosed Strike: $3.20	Not disclosed	Disclosure SEC source: 0001595262-16-000057 · edgar.xml · derivative · entry 4 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-07-20 F5 · price: This option was assumed by Quintiles in the merger and replaced with an option to purchase 7,680 shares of Quintiles IMS Holdings, Inc. common stock at a price of $8.34 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 22:50 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerEmployee Stock Optoin (right to buy) · Derivative	10,000	Not disclosed Strike: $5.80	Not disclosed	Disclosure SEC source: 0001595262-16-000057 · edgar.xml · derivative · entry 3 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-07-20 F4 · price: This option was assumed by Quintiles in the merger and replaced with an option to purchase 3,840 shares of Quintiles IMS Holdings, Inc. common stock at a price of $15.11 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 22:50 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerEmployee Stock Optoin (right to buy) · Derivative	20,000	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001595262-16-000057 · edgar.xml · derivative · entry 2 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-07-20 F3 · price: This option was assumed by Quintiles in the merger and replaced with an option to purchase 7,680 shares of Quintiles IMS Holdings, Inc. common stock at a price of $26.05 per share. Read SEC document
October 03, 2016 Filed Oct 3, 2016 22:50 UTC	IMS Health Holdings, Inc. IMS · Entity 174539	Disposition to issuerCommon Stock	42,840	Not disclosed	Not disclosed	Disclosure SEC source: 0001595262-16-000057 · edgar.xml · nonDerivative · entry 1 Mansukani Sharad · CIK 0001402190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 3, 2016, the issuer and Quintiles Transnational Holdings, Inc. ("Quintiles") entered into an Agreement and Plan of Merger pursuant to which on October 3, 2016 the issuer merged with and into Quintiles (the "merger"), the separate existence of the issuer ceased and Quintiles will continue as the surviving corporation, operating under the name Quintiles IMS Holdings, Inc. F2 · price: Disposed of pursuant to merger agreement in exchange for 16,450 shares of Quintiles IMS Holdings, Inc. stock having a market value of $81.06 per share at the effective time of the merger. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.